Our strategy

DDL's strategy is cost-effective development of new, safe and efficient drugs with a medical need, based on knowledge and, if possible, documentation that already exist.

Our technology is based on the following concepts:

• New drug molecules
• New innovative prodrugs of known drug substances
• New indications for old drugs
• New formulations

The Company's business strategy is to identify corporate partners for development, production, marketing and sales of products identified by DDL. Products will be licensed to larger pharmaceutical companies at the latest possible stage; typically clinical phase II/III.

What we do:

 innovative pharmaceutical research
 strategic protection of intellectual property

 organic synthesis

 analysis

 pharmaceutical formulations

 planning and conducting of clinical trials

 consultation activities / collaboration with other pharmaceutical companies